Last reviewed · How we verify
NCT05250570: DT-BD
Distress Tolerance for Benzodiazepine Discontinuation
NA trial testing Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) in Substance Use Disorders in 1 participant. Terminated before completion.
9 December 2022
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 17 June 2022 |
| Primary completion | 9 December 2022 |
| Estimated completion | 9 December 2022 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
- Relaxation Therapy
Conditions studied
- Substance Use Disorders — all drugs for Substance Use Disorders →
Sponsor
University of Pittsburgh
Who can join
18 and older, any sex, with Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy (OAT) who currently use benzodiazepines versus a Relaxation Therapy (RT) control condition. The DT-BD intervention is an adjunctive psychosocial intervention in people seeking to discontinue (BZD) use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05250570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
Trials testing the same drug.
- NCT04109118 — Benzodiazepine Discontinuation in Opioid Agonist Therapy · Phase 2 · completed
Other recruiting trials for Substance Use Disorders
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an · NA · recruiting
- NCT07281261 — tAN for Substance Use Disorder · NA · recruiting
- NCT07210268 — Temporal Interference Methods for Addiction Treatment · NA · recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05250570 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 30 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing